Benjamin A. Thuma
Pfizer (United States)(US)
Publications by Year
Research Areas
Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Diabetes Treatment and Management, Drug Transport and Resistance Mechanisms, Pancreatic function and diabetes
Most-Cited Works
- → Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing(2018)153 cited
- → Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors(2011)133 cited
- → Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor(2017)109 cited
- → Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose(2020)69 cited
- → Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK)(2017)49 cited
- → Development of an Early-Phase Bulk Enabling Route to Sodium-Dependent Glucose Cotransporter 2 Inhibitor Ertugliflozin(2014)43 cited
- → Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents(2018)43 cited
- → C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization(2010)43 cited
- → PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease(2020)41 cited
- → On the importance of synthetic organic chemistry in drug discovery: reflections on the discovery of antidiabetic agent ertugliflozin(2012)34 cited